Overall, our current findings are consistent with a growing body of evidence. Results from the Magrini et al trial, RTOG 0522 and GORTEC 2007‐01, multiple single institutional series, and a meta‐analysis all have pointed toward the nonequivalence of EGFR‐targeted and platinum‐based concurrent therapy during RT.